|
RealPennies.com: RealPennies.com: Turning Pennies into dollars:
(Nasdaq: NRWS), (OTCBB: PWRM), (OTCBB: HMBT).
(M2 PressWIRE Via Thomson Dialog NewsEdge)
RDATE:17012008
Are you a public company looking for exposure? Contact RealPennies.com
- 1.800.940.6559
For more info: http://nrws.realpennies.com
Narrowstep Inc. (Nasdaq: NRWS)(January 16, 2008), the TV on the
Internet company, announced earlier today that it has entered into a
partnership with Fox International's BabyTV, to provide their original
programming over the Internet using Narrowstep's platform.
BabyTV, www.babytvchannel.com, is the world's first TV channel
dedicated to infants and toddlers. Their innovative programming is
created by a team of award-winning content and child development
experts designed to promote learning, activity, interaction and fun.
BabyTV which launched internationally in 2005, is already viewed by
parents and babies worldwide on over 100 platforms in 65 different
countries and in 12 different languages. The channel is also available
through VOD, mobile, broadband, home videos, inflight services, and now
on www.babytvchannel.com.
Narrowstep will provide BabyTV with their telvOS Internet TV platform,
which is the most complete end-to-end solution for broadcasters to
deliver video over the Internet. telvOS provides broadcasters with a
suite of products and tools which includes a robust content management
system, superior DRM tools and a host of monetization tools. These
tools allow broadcasters to effectively integrate a customized Internet
TV strategy into their existing workflow without the need to deal with
multiple vendors.
Narrowstep also designed and built the feature-rich video player. The
BabyTV player is a complementary experience to viewing the channel
which allows parents to choose their child's favorite programs by
themes or by character, and allows parents and babies to engage in
activities such as Baby Karaoke, sing along and more. The player also
offers parents the option of tailoring their child's experience by
viewing the programming in a number of different languages.
Narrowstep recently announced the release of its Player 2.7 technology
designed to provide global broadcasters and telcos with the tools they
need to monetize video over the internet. Fox's BabyTV is the latest
addition to Narrowstep's world-class list of clients including ITV
Local, Virgin, Telefonica, Sci Fi Channel, KPN, the Outdoor Channel,
the Travel Channel and more.
Narrowstep Inc. (OTCBB:NRWS), the TV on the Internet company, is a
leading provider of Internet TV services supporting over 180 channels
worldwide. Narrowstep's proprietary technology platform delivers the
highest quality, TV-like experience available on the Internet. A
pioneer in delivering Internet TV, Narrowstep offers the expertise and
technology to move, manage and monetize video content across the
Internet. For more information about Narrowstep, please visit
http://www.narrowstep.com or call 609-945-1760.
About Baby TV BabyTV is the world's first 24 hour, commercial-free
channel for infants and toddlers and their parents. Created by a team
of award-winning content experts and leading childhood experts, BabyTV
is a unique offering of dedicated programs designed to promote early
learning, activity, interaction and fun. Since its first launch, BabyTV
has seen rapid growth and is currently aired on over 100 platforms in
more than 65 countries worldwide. For more information please visit our
website www.babytvchannel.com.
For more info: http://pwrm.realpennies.com
Earlier today Power3 Medical Products, Inc. (OTCBB: PWRM)(January 16,
2008), a leading proteomics company specializing in the development and
commercialization of diagnostic tests for the early detection of breast
cancer and neurodegenerative diseases, announced that they were
featured on Fox26 News in Houston.
The segment focused on Power3's blood serum tests for the early
detection of breast cancer and neurodegenerative diseases. News anchor
Melissa Wilson toured Power3's facilities in the Woodlands, Texas and
interviewed Steve Rash, CEO of Power3 along with two of the company's
lead investigators, Dr. Essam Sheta and Dr. Ira Goldknopf.
During the interview, Steve Rash discussed the BC-SeraPro early
detection test for breast cancer. "It is a goal of Power3 Medical to
help women because breast cancer is such a terrible disease and there
is so much emphasis on the disease," said Rash. "This test can detect
it earlier, which should result in better patient outcomes for breast
cancer in most women."
The piece discussed the need for alternative methods of early
detection, citing that some research has found that current methods
detect breast cancer after abnormal cells have been in the body for six
to ten years. In addition to BC-SeraPro, the piece highlights the
company's NuroPro series of blood serum tests for the early detection
of neurodegenerative diseases. The story also drew attention to the
accuracy of the tests: BC-Sera Pro test for the early detection of
breast cancer is 90% accurate; NuroPro test for neurodegenerative
diseases is 90% accurate in detecting Alzheimer's disease and 100%
accurate in detecting Parkinson's disease.
Dr. Goldknopf added, "If you can diagnose Neurodegenerative diseases in
their earliest stages, before irreversible damage has been done, you
stand a better chance of delaying the progression of the disease."
Power3 Medical Products, Inc. (OTCBB: PWRM, www.Power3Medical.com), is
a leading proteomics company engaged in the commercialization of
protein biomarkers, pathways, and mechanisms of diseases through the
development of diagnostic tests and drug targets for cancer and
neurodegenerative diseases. Power3's patent-pending technologies are
being used to develop screening and diagnostic tests for the early
detection and prognosis of disease, identify protein biomarkers, and
drug targets. Diagnostic tests are targeted toward markets with
critical unmet needs in areas such as breast cancer and
neurodegenerative disease. Power3 has signed its first distribution
agreement to provide its blood serum diagnostic for breast cancer,
BC-SeraPro, in twelve Middle Eastern countries before the end of 2007.
Power3 operates a state-of-the-art CLIA certified proteomics laboratory
in The Woodlands (Houston), Texas. The Company is preparing to
commercialize its IP portfolio, centering on the 543 biomarkers the
Company has discovered from a broad range of diseases as the basis of
blood-based tests for breast cancer, ALS, Alzheimer's, and Parkinson's
Diseases.
For more info: http://hmbt.realpennies.com
Earlier today HemoBioTech (OTCBB: HMBT)(January 16, 2008), a
developmental biopharmaceutical company focused on developing and
commercializing the first viable human blood substitute, announced that
they have been highlighted in the January 5-11th issue of New Scientist.
The article, "Fresh Hope For Emergency Blood Substitutes" concerns
HemoBioTech's lead product, HemoTech, and describes the technology
platform's potential ability to become a safe, inexpensive,
oxygen-carrying human blood substitute. In the piece, Chief Executive
Officer Dr. Arthur Bollon indicated that in an initial foreign clinical
study where patients received HemoTech comprising 25% of their blood
volume, the substitute made blood vessels dilate, showed no kidney
toxicity, caused no inflammation and even stimulated production of new
red blood cells. HemoTech, which induces red blood cell production, is
designed to provide a blood replacement when otherwise unavailable and
has been showing positive results.
"We are pleased to have national publications like New Scientist find
both relevance and excitement in our emerging technology," said Dr.
Bollon. "Our ability to isolate and nullify the source of toxicity that
has plagued many companies' past attempts creates both a significant
commercial and medical opportunity that, if approved, will be a great
asset to the broad blood use market."
New Scientist is a magazine publication that has been at the forefront
of science and technology reporting since 1956. With New Scientist
magazine, every week a comprehensive round-up of the latest science and
technology news, reports, developments and research is distributed.
Employing correspondents in every corner of the globe who contact
leading scientists, New Scientist has the ability to scan thousands of
journals and scientific websites to deliver the most up to date news to
the public. Every issue provides the latest news across every field of
science, features containing in-depth analysis and investigations of
key scientific issues from our expert team of writers, the latest
trends in emerging technologies and devices that could change the way
we live and work, commentary, interviews, and job vacancies.
About HemoBioTech, Inc.
HemoBioTech is working on the development and commercialization of
HemoTech, a novel human blood substitute technology exclusively
licensed from Texas Tech University Health Sciences Center. HemoTech is
composed of bovine hemoglobin that is chemically modified with
adenosine triphosphate, adenosine, and glutathione. In addition to
carrying oxygen through the bloodstream, HemoTech also induces
erythropoiesis (red blood cell production). Based on preclinical
studies and an initial foreign human clinical study, the company
believes that HemoTech, due to its novel chemical composition, may
significantly diminish or even eliminate the intrinsic toxicities that
have plagued other attempts at developing blood substitutes. HemoTech
is currently undergoing additional studies to confirm and possibly
expand on these results. HemoTech is being developed to help reduce or
eliminate the danger resulting from acute blood loss in trauma,
surgery, and other conditions. Corporate headquarters are located at
5001 Spring Valley Road, Suite 1040-West, Dallas, Texas 75244. For
further information visit our website at http://www.hemobiotech.com.
Read our full disclaimer at: http://www.realpennies.com/start.html
Investors are advised that this analysis is issued solely for
informational purposes and is not to be construed as an offer to sell
or the solicitation of an offer to buy. This report does not have
regard to the specific investment objectives, financial situation and
the particular needs of any specific person who may receive this
information. The information contained herein is based on sources that
we believe to be reliable but is not guaranteed by us as being accurate
and does not purport to be a complete statement or summary of the
available data. Past performance is no guarantee of future results.
Please consult a broker before purchasing or selling any securities
mentioned on RealPennies. For more movers:
http://www.realpennies.com/wrapup.html
Any opinions expressed herein are statements of our judgment as of the
date of publication and are subject to change without notice.
Sitemap: http://www.realpennies.com/sitemap.html
CONTACT: RealPennies
Tel: +1 800 940 6559
e-mail: Matt@realpennies.com
((M2 Communications Ltd disclaims all liability for information
provided within M2 PressWIRE. Data supplied by named party/parties.
Further information on M2 PressWIRE can be obtained at
http://www.presswire.net on the world wide web. Inquiries to
info@m2.com)).
Copyright ? 2008 M2 Communications Ltd.
[ Back To cable.tmcnet.com's Homepage ]
|